Living with a Disease

HER2-mutant advanced Non-Small Cell Lung Cancer (NSCLC)

Based on 2022 data, it is estimated that among the ~2 million people diagnosed with non small cell lung cancer (NSCLC) globally, about 60,000 have an activating HER2 mutation. [1–3]

We’re committed to helping everyone with lung cancer – and that means advocating for patients with even the rarest of mutations. By raising awareness of HER2-mutant NSCLC and the unmet needs many still face, we can help make a real difference for the people who need it most, your patients.

But first, here’s a reminder of precisely why we do it…

Let's look closer at HER2

HER2-mutant NSCLC was first identified in 2004,4 but there s still much to learn about this devastating diagnosis.4–6 Here are some of the key things to know:

While activating HER2 mutations are rare, anyone with advanced NSCLC could have a HER2 driver mutation.3,4 And for the 2-4% of patients who do have it,3,4 time is of the essence. Because patients with these mutations may face a worse prognosis than those with other driver mutations7,9 and the impact on people's lives 
is immeasurable.

That's why we won't stop researching and innovating within HER2 and beyond.  
And you have a role to play too. By learning more about HER2 and the impact it can have, you can help shape real people's next steps forward.

Watch the video below for expert insights and information.

Next generation sequencing (NGS) delivers precise answers

Being able to accurately identify HER2 mutant NSCLC is crucial to determining the right path for each patient.10–12

One way to bring precision to your diagnostic practice is through NGS – a DNA or RNA sequencing technology that can detect the broad spectrum of genomic HER2 alterations.10

Since activating HER2 mutations and overexpression are two distinct alterations in NSCLC,10 different tests are needed. NGS is needed to comprehensively identify activating HER2 mutations whereas immunohistochemistry (IHC) should be used to detect HER2 overexpression.10–12

Hear from Dr. Loong below to discover why an NGS test is always important to consider for people with advanced NSCLC.10–1

Change starts with a change

We know there's still more to do in HER2 mutant NSCLC. More research, more innovation, more people filling every moment with life. And while we're investing in ways to better understand and support the complexities of this disease, you can help make a real difference today.

Even these seemingly small changes to your day to day actions surrounding HER2 can have a big impact reaching real people and transforming real lives.

So, let's keep changing for the better and push for more momentum in HER2-mutant NSCLC, together.

Sources:

  1. Bray F, et al. CA Cancer J Clin. 2024;74(3)229-263.
  2. Sharma R. Int J Clin Oncol. 2022;27(4):665-675.
  3. Yu X et al. Front Oncol. 2022;12:860313.
  4. Stephens P, et al. Nature. 2004;431(7008):525-526.
  5. Mitchell CL, et al. Diagnostics (Basel). 2023;13(6):1117.
  6. Uy NF, et al. Cancers (Basel). 2022;14(17):4155.
  7. Yang S, et al. Transl Lung Cancer Res. 2021;10(2):753-765.
  8. Offin M, et al. Cancer. 2019;125(24):4380-4387.
  9. Wang Y, et al. BMC Cancer. 2018;18(1):326.
  10. IASLC  Atlas of Molecular Testing for Targeted Therapy in Lung 
    Cancer. International Association for the Study of Lung Cancer. February 2023.
  11. Hendriks LE, et al. Ann Oncol. 2023;34(4):339-357.
  12. Puri S, et al. J Clin Oncol. Published online February 3, 2026.
  13. Kerr KM, et al. Lung Cancer. 2021;154:161-175

Discover more

Bayer Treatment

Lore ipsum (see other cancer types)

Explore More

PP-UN-ONC-ALL-0059-1